A Research Guide for
Facing Huntington’s Disease

FDA-APPROVED Deutetrabenazine is a deuterated form of tetrabenazine that provides more stable blood levels and fewer side effects. In the FIRST-HD trial, it significantly reduced chorea compared to placebo while causing less sedation, depression, and parkinsonism than tetrabenazine. It is taken twice daily and has become the preferred VMAT2 inhibitor for most HD patients.

BIOMARKER Neurofilament light chain (NfL) is a protein released into cerebrospinal fluid and blood when neurons are damaged. Multiple studies (HDClarity, TRACK-HD, Predict-HD) have shown that NfL levels rise years before motor symptom onset in HD gene carriers and correlate with disease progression. NfL is now used as a key secondary endpoint in clinical trials and may eventually help guide when to start disease-modifying therapy.

BIOMARKER Sensitive assays can now measure the concentration of the mutant huntingtin protein (mHTT) in CSF. This has been used to confirm target engagement in gene-silencing trials — showing that antisense oligonucleotides successfully reduce mHTT production in the brain. CSF mHTT remains a critical pharmacodynamic biomarker for all HTT-lowering programs.

FDA-APPROVED Valbenazine, a selective VMAT2 inhibitor originally approved for tardive dyskinesia, has demonstrated efficacy in the KINECT-HD trial for HD chorea. FDA approval for the HD indication was granted in 2023. Its once-daily dosing and favorable side effect profile make it another option for chorea management.

INVESTIGATIONAL The concept of gene silencing — reducing production of the toxic mutant huntingtin protein at the RNA level — remains the most scientifically promising approach to modifying HD. Although the first major Phase 3 trial (tominersen/GENERATION-HD1) was stopped for futility and potential harm in 2021, the scientific rationale remains strong. Next-generation approaches aim to selectively silence only the mutant copy of HTT (allele-selective silencing), spare the normal copy, use improved delivery methods, and find the right dose and timing. Multiple programs are in clinical trials.

CAG repeats are unstable during DNA replication, particularly during sperm formation. This means the repeat length can increase when passed from parent to child, especially from father to child. This phenomenon — called anticipation — explains why some families see earlier onset in successive generations. Juvenile HD (onset before age 20) almost always results from very large expansions (often 60+ repeats) transmitted by the father.

• Testing is always voluntary. No one should be pressured into testing. Many at-risk individuals choose not to be tested, and that is a valid and respected choice.
• Genetic counseling is mandatory. All HD testing programs require pre-test genetic counseling (typically 2–3 sessions) and post-test follow-up. This is not a formality — it is essential for informed decision-making and emotional preparation.
• Results cannot be undone. Once you know your gene status, you cannot un-know it. This information affects not only you but potentially siblings and children.
• Insurance implications. The Genetic Information Nondiscrimination Act (GINA) protects against discrimination by health insurers and employers based on genetic test results. However, GINA does not cover life insurance, disability insurance, or long-term care insurance. Consider securing these policies before testing.
• Emotional impact. Both positive and negative results can cause significant psychological distress. Survivor guilt is common in those who test negative when siblings test positive. Depression and suicidal ideation can occur after positive results. Professional psychological support should be arranged in advance.

• Predictive testing: For at-risk individuals who have no symptoms. Determines gene status before disease onset.
• Diagnostic testing: For individuals already showing symptoms consistent with HD. Confirms or rules out HD as the cause.
• Prenatal testing: Can be performed during pregnancy (chorionic villus sampling or amniocentesis) to determine whether the fetus carries the expansion. Raises complex ethical questions.
• Preimplantation genetic testing (PGT): Used with in vitro fertilization (IVF) to select embryos that do not carry the HD expansion. Allows at-risk parents to have children without the HD gene without needing to know their own gene status (exclusion testing is possible).

• Should I undergo predictive genetic testing, and what are the arguments for and against in my situation?
• What protections do I have against insurance or employment discrimination?
• Should I secure life insurance or disability insurance before testing?
• How will this result affect my family planning options?
• What psychological support is available before and after testing?
• If I test positive, what monitoring should I start and how often?
• Can my children be tested, and at what age is that appropriate?
• Are there clinical trials that I could participate in based on my gene status, even before symptoms start?

• What stage of HD am I in based on the Unified Huntington’s Disease Rating Scale (UHDRS)?
• What changes should I expect in the next 1–2 years?
• When should I stop driving?
• When should we begin planning for increased care needs?
• Are there clinical trials for my current stage?
• When should we discuss advance directives and long-term care planning?

FDA-APPROVED Deutetrabenazine is a VMAT2 (vesicular monoamine transporter 2) inhibitor that reduces dopamine signaling. It was approved by the FDA in 2017 based on the FIRST-HD trial. Key advantages over tetrabenazine include twice-daily dosing (vs. three times daily), more stable plasma levels, and fewer side effects including less sedation and depression. Typical dose range is 12–48 mg/day in two divided doses. Requires CYP2D6 metabolizer testing before exceeding 36 mg/day.

FDA-APPROVED Tetrabenazine was the first FDA-approved treatment specifically for HD chorea (2008). While effective, it has a shorter half-life requiring three-times-daily dosing and higher rates of depression, sedation, parkinsonism, and akathisia compared to deutetrabenazine. It carries a black box warning for depression and suicidality. Still used when deutetrabenazine is not available or not tolerated.

FDA-APPROVED Valbenazine, another selective VMAT2 inhibitor, demonstrated efficacy in reducing HD chorea in the KINECT-HD trial. Its once-daily dosing is convenient, and it has a favorable side effect profile. Approved for HD chorea in 2023.

• Amantadine: Sometimes used off-label for chorea at doses of 200–400 mg/day. Evidence is limited and mixed, but may help some patients. Also may help with fatigue.
• Antipsychotics (risperidone, olanzapine, haloperidol): Can suppress chorea through dopamine blockade. Useful when psychiatric symptoms (irritability, psychosis) coexist with chorea, as they treat both. However, they carry risks of parkinsonism, sedation, metabolic syndrome, and tardive dyskinesia.
• Benzodiazepines (clonazepam): Occasionally used for chorea and anxiety but risk sedation, falls, and cognitive worsening. Use with caution in HD.

• Is my chorea severe enough to warrant medication, or should we monitor?
• Which VMAT2 inhibitor do you recommend, and why?
• What are the side effects I should watch for, especially depression?
• Do I need CYP2D6 testing before starting medication?
• How will we monitor for worsening depression or suicidal thoughts?
• Can my chorea medication worsen other symptoms like swallowing or balance?

Depression in HD is extremely common and is both a reaction to the diagnosis and a direct result of brain changes caused by the disease. It is treatable.

• SSRIs (citalopram, sertraline, fluoxetine): First-line. Generally well tolerated. Sertraline and citalopram are commonly used.
• Mirtazapine: Useful when insomnia and weight loss are prominent. May help with appetite stimulation.
• SNRIs (venlafaxine, duloxetine): Alternative when SSRIs are insufficient.
• Suicide risk: HD carries a 4–8x increased suicide risk compared to the general population. Risk is highest around the time of genetic testing/diagnosis and when independence is lost. Every clinical visit should include screening for suicidal ideation. Do not avoid asking about suicide — asking does not cause it.

Irritability is one of the most common and disruptive symptoms. It can range from mild impatience to explosive outbursts that strain relationships and endanger family members.

• SSRIs: First-line for irritability as well as depression.
• Atypical antipsychotics (olanzapine 2.5–10 mg, risperidone 0.5–2 mg, quetiapine 25–200 mg): Used for moderate-to-severe irritability or when aggression is present.
• Mood stabilizers (valproate, carbamazepine): Sometimes helpful for persistent irritability not responsive to SSRIs or antipsychotics.
• Behavioral strategies: Structured routines, reduced stimulation, clear communication, and environmental modifications are as important as medication.

Apathy — a loss of motivation, initiative, and emotional responsiveness — is extremely common in HD and distinct from depression (though they often coexist). Apathy is often more distressing to caregivers than to patients, who may not recognize it. Unfortunately, apathy is one of the hardest HD symptoms to treat.

• No medication has strong evidence for HD apathy specifically.
• SSRIs may help if depression coexists, but can sometimes worsen apathy.
• Structured daily routines and scheduled activities help more than medication.
• Stimulants (methylphenidate) and bupropion are sometimes tried but evidence is limited.

• SSRIs: First-line treatment for both anxiety and OCD-like behaviors in HD.
• Buspirone: May be helpful for anxiety without sedation.
• Benzodiazepines: Avoid if possible due to cognitive and fall risks. Short-term use only when necessary.
• Perseverative behaviors (getting “stuck” on thoughts or actions) are common in HD and overlap with OCD. They often respond to SSRIs at higher doses (similar to OCD dosing).

Psychosis (hallucinations, delusions) occurs in approximately 5–10% of HD patients, typically in later stages. Treatment with low-dose atypical antipsychotics (olanzapine, risperidone, quetiapine) is generally effective. Note that antipsychotics also suppress chorea, which may be beneficial or may cause excessive rigidity — dose must be carefully balanced.

• Am I being screened for depression and suicidal thoughts at every visit?
• Should I be taking an antidepressant, and which one is best for my specific symptoms?
• Is my irritability a symptom of HD or a medication side effect?
• Can you help my family understand that my behavioral changes are part of the disease?
• Should I see a psychiatrist experienced with HD?
• What behavioral strategies can help alongside medication?

• Difficulty with complex tasks (managing finances, cooking multi-step meals, following complex instructions)
• Slowed thinking and response time
• Impaired judgment and decision-making
• Difficulty multitasking
• Rigid thinking — trouble adapting to changes in routine
• Word-finding difficulties (but language is generally better preserved than in Alzheimer’s)
• Late stages: severe dementia requiring full-time supervision

• No medication slows cognitive decline in HD. Cholinesterase inhibitors (donepezil, rivastigmine) used in Alzheimer’s have not shown benefit in HD and are generally not recommended.
• Treat underlying depression. Depression alone can worsen cognitive function. Adequate antidepressant treatment may improve cognition.
• Simplify the environment. Reduce clutter, establish predictable routines, use visual cues and checklists, break tasks into simple steps.
• Speech-language therapy can provide cognitive-communication strategies.
• Occupational therapy helps develop compensatory strategies for daily tasks.
• Plan early. Advance directives, power of attorney, financial planning, and long-term care arrangements should be addressed while the person can still participate in decisions.

• Regular exercise has been shown in multiple studies (ENGAGE-HD, EXERT-HD) to improve gait, balance, and fitness in HD patients.
• Physical therapy focuses on balance training, fall prevention, gait optimization, and maintaining mobility.
• Exercise may have neuroprotective effects, though this is not yet proven in HD.
• Continue exercise and physical therapy throughout all stages, adapting to changing abilities.

• Dysarthria (slurred speech) is common. Speech therapy can help maintain communication for longer through compensatory strategies.
• Dysphagia (swallowing difficulty) is a major safety concern and the leading cause of death in late-stage HD (aspiration pneumonia). Swallowing evaluations should be performed regularly.
• Dietary modifications (thickened liquids, pureed foods, supervised meals) reduce aspiration risk.
• Feeding tube decisions should be discussed early as part of advance care planning. Percutaneous endoscopic gastrostomy (PEG) tubes are sometimes used but remain a personal and values-based decision.

• HD patients often have high caloric needs due to constant involuntary movements (chorea burns calories).
• Weight loss is common and is associated with faster disease progression in some studies.
• High-calorie, nutrient-dense foods are recommended. Do not restrict calories unless there is a specific medical reason.
• Regular weight monitoring is important. Dietary counseling from a nutritionist familiar with HD is valuable.

• HD chorea medicines can be expensive. Deutetrabenazine (Austedo) and valbenazine (Ingrezza) may cost thousands of dollars a month at list price. Do not assume you cannot afford them — assistance is usually available.
• Manufacturer copay & patient-assistance programs: Austedo (Teva) and Ingrezza (Neurocrine) both offer copay-savings cards for people with commercial insurance and patient-assistance programs (free or reduced-cost medicine) for those who qualify by income. Tetrabenazine (Xenazine) also has a much cheaper generic version. Ask the prescriber or an HD-center social worker to start the application.
• Disability income: HD — including juvenile HD — qualifies for Social Security Disability Insurance (SSDI) under the Social Security Compassionate Allowances program, which speeds up approval.
• Insurance help: a hospital or HD-center social worker can assist with prior authorizations, appeals if a medicine is denied, Medicare/Medicaid enrollment, and charitable copay foundations.
• HDSA support: the HDSA helpline (1-800-345-HDSA) can connect you with social workers and local financial and insurance resources.

• Should I have a swallowing evaluation, and how often?
• What kind of exercise is safe for me at my current stage?
• Am I losing weight, and should I be eating more?
• Can I still drive safely?
• Should I be seeing a speech therapist?
• When should we start discussing advance directives and care planning?

FAILED PHASE 3 Tominersen was an antisense oligonucleotide (ASO) delivered by intrathecal injection (spinal tap) every 8 or 16 weeks. It targets both mutant and normal huntingtin mRNA (non-allele-selective). The Phase 1/2 trial showed a dose-dependent reduction in CSF mHTT. However, the Phase 3 GENERATION-HD1 trial (NCT03761849) was stopped in March 2021 by the independent data monitoring committee due to a worse outcome in the treated group compared to placebo. Higher doses and younger patients with less disease burden appeared to be most affected. The failure prompted a fundamental reassessment of HTT-lowering strategy, dosing, timing, and the importance of allele selectivity.

INVESTIGATIONAL WVE-003 is an allele-selective antisense oligonucleotide that targets a specific single nucleotide polymorphism (SNP) associated with the expanded HTT allele (rs362307, present in approximately 40% of HD patients). This approach aims to silence only the mutant HTT copy while preserving the normal copy. The SELECT-HD trial (NCT05032196) showed selective reduction of mutant HTT in CSF. Development continues, with Phase 2 expansion underway.

• AMT-130 (uniQure): An AAV5-delivered microRNA gene therapy targeting HTT, given as a one-time surgical injection into the striatum. The Phase I/II trial (NCT04120493) reported positive topline results — the high dose slowed clinical decline compared with a natural-history comparison group, with a marker of brain-cell injury (NfL) falling below the starting level. It has received FDA Breakthrough Therapy and RMAT designations. The regulatory path is still being worked out: in March 2026 the FDA recommended an additional randomized study (with a sham-surgery comparison) before approval, so the timing is uncertain. Potential advantage: a single procedure rather than repeated injections.
• PTC518 / votoplam (PTC Therapeutics, now partnered with Novartis): An oral once-daily small molecule that lowers the huntingtin protein. The Phase 2 PIVOT-HD trial (NCT05358717) met its main goal of lowering huntingtin in the blood, and a 24-month follow-up reported in 2026 suggested meaningful slowing of disease progression at the higher dose. Novartis took over development in late 2024 and has launched a large Phase 3 trial (INVEST-HD). Because it is an oral pill rather than an injection or surgery, this is one of the most closely watched programs in HD.
• CRISPR-based approaches: Preclinical programs are exploring permanent gene editing to inactivate the expanded HTT allele. Not yet in human trials for HD. Potential for a one-time cure, but safety and delivery challenges remain substantial.

• EHDN (European Huntington’s Disease Network): Coordinates HD research and care across Europe. Publishes standards of care.
• HSG (Huntington Study Group): North American research network. Conducts and coordinates clinical trials.
• CHDI Foundation: The largest private funder of HD research globally. Manages the HD Trial Finder and supports target identification and drug development.
• Enroll-HD: Global observational platform with sites in 20+ countries.
• Huntington’s Disease Youth Organization (HDYO): Support and education for young people affected by HD internationally.
• International Huntington Association (IHA): Umbrella organization for national HD associations worldwide.

HD prevalence varies dramatically by ancestry:

• European ancestry: 5–10 per 100,000 (highest prevalence globally)
• East Asian: 0.5–1 per 100,000 (much lower; shorter CAG repeat distributions in the general population)
• African: Limited epidemiologic data; appears lower than European populations
• Latin America: Variable; the Lake Maracaibo, Venezuela cluster has exceptionally high prevalence due to a founder effect

FAILED The Phase 3 GENERATION-HD1 trial (NCT03761849) was the largest and most anticipated HD trial in history. It enrolled 791 patients and tested tominersen, a non-selective HTT-lowering ASO, given by intrathecal injection. The trial was stopped in March 2021 when the independent monitoring committee found that treated patients were doing worse than placebo, not better. Post-hoc analyses suggested younger patients and those receiving higher doses were most adversely affected. Possible explanations include excessive lowering of normal huntingtin, neuroinflammation from intrathecal delivery, or wrong timing/dose. A follow-up study (GENERATION-HD2) is testing lower doses in a more select population.

FAILED Laquinimod, an immunomodulatory drug originally developed for multiple sclerosis, was tested in the LEGATO-HD Phase 2 trial (NCT02215616) based on the hypothesis that neuroinflammation contributes to HD progression. While it showed a modest reduction in caudate volume loss on MRI, it did not improve motor function (the primary endpoint). Development for HD was discontinued.

FAILED Pridopidine, a sigma-1 receptor agonist, was tested in multiple HD trials. The Phase 3 PROOF-HD trial failed to meet its primary endpoint of change in Total Functional Capacity (TFC). Earlier Phase 2 trials (PRIDE-HD, MermaiHD) also failed their primary endpoints, though there were signals in post-hoc analyses. Development has been re-evaluated.

DE-ADOPTED Coenzyme Q10 (2CARE trial, NCT00608881) and creatine (CREST-E trial, NCT00712426) were tested in large, rigorous trials based on the hypothesis that mitochondrial dysfunction drives HD. Both trials were stopped early for futility — neither supplement slowed disease progression. While generally safe, they should not be considered therapeutic for HD.

FAILED Ethyl-eicosapentaenoic acid (ethyl-EPA), an omega-3 fatty acid derivative, was tested in the TREND-HD trial. It failed to show any benefit on motor or functional measures. Development was discontinued.

• Are there any clinical trials currently enrolling for my stage of HD?
• Am I eligible for any gene-silencing trials?
• Should I enroll in Enroll-HD or HDClarity?
• What is the latest on disease-modifying therapies?
• Are any of the gene therapy approaches near approval?
• Should my presymptomatic family members be aware of trials for gene carriers?

• The irritability and outbursts are the disease. HD damages the brain circuits that regulate impulse control and emotional regulation. When your loved one is irritable, rigid, or aggressive, that is the disease process, not a choice. Understanding this does not make it easy, but it helps.
• Apathy is not laziness. The person with HD may sit and stare, refuse to participate in activities they once enjoyed, or seem not to care. This is apathy, a core symptom of HD, not depression or defiance. Structured routines and gentle redirection help more than persuasion.
• Perseveration is common. Repeating questions, getting “stuck” on topics, or inability to shift focus is part of the cognitive decline. Respond patiently, redirect gently, avoid arguing.

• Remove tripping hazards (rugs, cords). Install grab bars in bathroom. Consider a shower chair.
• Supervise meals when dysphagia develops. Learn the Heimlich maneuver. Cut food into small pieces. Allow plenty of time for eating.
• Assess driving safety early and regularly. Loss of driving ability is common and emotionally difficult. An occupational therapy driving evaluation can provide objective data.
• Secure firearms and hazardous materials. Suicide risk is elevated throughout HD, and impulsivity is a core feature of the disease.
• Install smoke detectors and consider stove safety devices.

• Complete advance directives early. Healthcare power of attorney, living will, and financial power of attorney should be completed while the person can still participate meaningfully in decisions.
• Consider long-term care needs. HD requires increasing levels of care over many years. Explore options: home care, adult day programs, residential care, hospice.
• Financial resources: Social Security Disability Insurance (SSDI) is available for HD (HD qualifies under the Compassionate Allowances program for expedited processing). Contact the HDSA social worker for guidance.
• HDSA caregiver resources: Call the HDSA helpline at 1-800-345-HDSA (4372) or visit hdsa.org for caregiver support groups, educational materials, and social service referrals.

• Caregiver burnout in HD is the rule, not the exception. The slow progression, behavioral changes, and genetic implications for children make HD caregiving uniquely stressful.
• Use respite care. Regular breaks are not optional — they are essential for your health and your ability to continue caregiving.
• Join a support group. HDSA support groups (in-person and virtual) connect you with others who understand. The shared experience is irreplaceable.
• Seek therapy. Individual counseling can help with grief (grieving someone who is still alive), family dynamics, and the genetic anxiety that affects many HD families.
• Address your own at-risk status. If you are the biological child of someone with HD, you may be processing your own genetic risk while also caregiving. This dual burden deserves professional support.

• “Huntington disease deutetrabenazine FIRST-HD”
• “valbenazine Huntington chorea KINECT-HD”
• “tetrabenazine Huntington disease chorea”
• “Huntington disease depression SSRI”
• “Huntington disease dysphagia management”
• “Huntington disease exercise physical therapy”

• “tominersen GENERATION-HD1”
• “WVE-003 allele selective Huntington”
• “AMT-130 gene therapy Huntington”
• “PTC518 splicing modifier Huntington”
• “neurofilament light Huntington biomarker”
• “mutant huntingtin protein lowering”